Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023 [Yahoo! Finance]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Yahoo! Finance
Total Revenue : Full year 2023 total revenues reached $607.5 million, with a non-GAAP increase of 26% excluding Trokendi XR net product sales. Operating Earnings : Operating loss (GAAP) was $(5.3) million for 2023, with non-GAAP operating earnings of $125.1 million. Net Earnings : Net earnings (GAAP) for the full year stood at $1.3 million, with diluted earnings per share at $0.02. Balance Sheet : Cash, cash equivalents, and marketable securities were approximately $271.5 million as of December 31, 2023. 2024 Financial Guidance : Total revenue guidance set at $580 million to $620 million, with non-GAAP operating earnings projected between $80 million and $110 million. Warning! GuruFocus has detected 7 Warning Signs with SUPN. On February 27, 2024, Supernus Pharmaceuticals Inc ( NASDAQ:SUPN ) released its 8-K filing , announcing financial results for the fourth quarter and full year of 2023. The company, a specialty pharmaceutical firm engaged in developing and commerciali
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures [Yahoo! Finance]Yahoo! Finance
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresGlobeNewswire
- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics [Yahoo! Finance]Yahoo! Finance
SUPN
Earnings
- 5/8/24 - Miss
SUPN
Sec Filings
- 5/9/24 - Form 8-K
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- SUPN's page on the SEC website